医学
肺癌
内科学
癌症
肿瘤科
疾病
癌症研究
肺
肺病
乳腺癌
摘要
To the Editor: In the Beamion LUNG-1 multicohort trial, Heymach et al. (April 30 issue) 1 showed that zongertinib had a compelling efficacy and safety profile in patients with untreated non–small-cell lung cancer (NSCLC) and a documented HER2 mutation, with outcomes that compare favorably with the current standard of care. Although zongertinib is a welcome addition to the treatment options for HER2 -mutant NSCLC, improving the intracranial activity of the drug remains a clinical priority. The median systemic progression-free survival among patients who had not previously received treatment (cohort 2) was 14.4 months, but the median intracranial progression-free survival among patients with . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI